Is PT-141 (Bremelanotide) Legal in Louisiana?

What PT-141 (Bremelanotide) Is and Why Its Legal Status Matters

PT-141, sold under the brand name Vyleesi, is a melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors in the brain to increase sexual desire. The FDA approved Vyleesi on June 21, 2019, making bremelanotide the second FDA-approved pharmacologic treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, following flibanserin (Addyi) in 2015. [1]

Unlike testosterone or certain peptides that exist purely in research-chemical territory, bremelanotide has a clear regulatory identity: it is an FDA-approved drug. That status shapes every question about legality, compounding, and prescribing.

Why Federal Law Governs First

Louisiana does not have a separate state statute that independently regulates bremelanotide. State pharmacy and medical practice law in Louisiana layers on top of the federal Food, Drug, and Cosmetic Act (FD&C Act) rather than replacing it. That means the FDA's approval decision, its bulk-drug compounding lists, and DEA scheduling rules are the foundation. [2]

DEA Scheduling

Bremelanotide is not listed as a Schedule I, II, III, IV, or V controlled substance under the Controlled Substances Act. [3] Possession of the FDA-approved Vyleesi product with a valid prescription therefore carries no controlled-substance charge risk under federal law. Possession of a compounded or gray-market version without a prescription is a different matter and could implicate the FD&C Act's prohibition on dispensing prescription drugs without a valid order.

Federal FDA Framework: Approved Drug Versus Compounded Bremelanotide

The Vyleesi Approval

The FDA approved Vyleesi (bremelanotide injection, 1.75 mg/0.3 mL) for premenopausal women with acquired, generalized HSDD based on two Phase 3 randomized controlled trials (RECONNECT), in which bremelanotide produced statistically significant improvements in desire (P<0.001) and distress scores versus placebo over 24 weeks. [4] The prescribing information notes nausea (approximately 40% of patients), flushing, and transient blood pressure increases as the most common adverse effects. [1]

Because an FDA-approved finished product exists, compounding pharmacies face a higher legal bar. Under 21 U.S.C. § 503A, a 503A pharmacy may compound a drug that is essentially a copy of a commercially available product only if the prescriber documents that the commercially available product does not meet the patient's clinical need, such as a documented allergy to an excipient. [5]

The 503B Outsourcing Facility Pathway

503B outsourcing facilities operate under different rules. They may compound without patient-specific prescriptions but must use bulk drug substances that appear on the FDA's 503B bulk-drug list. As of early 2025, bremelanotide does not appear on the FDA's affirmative 503B bulk-drug list (Category 1). [6] The FDA has placed bremelanotide on its Category 2 list of substances nominated for evaluation where a final determination has not yet been published. Compounding by 503B facilities therefore remains in legal gray territory until the FDA issues a final determination. [6]

What "Gray Area" Means in Practice

"Gray area" does not mean illegal for 503A purposes. A 503A pharmacy with a patient-specific prescription and a documented clinical rationale can compound bremelanotide lawfully today, provided it meets USP standards and the patient's prescriber has documented the medical necessity. It does mean that patients and providers should actively confirm their pharmacy's compliance status rather than assume it.

Louisiana State-Level Rules for Bremelanotide

Louisiana Board of Pharmacy

The Louisiana Board of Pharmacy (LBP) regulates pharmacy practice under Louisiana Revised Statutes Title 37, Chapter 14. The LBP does not maintain a separate list of banned peptides. Instead, it requires compounding pharmacies operating in Louisiana, or shipping into Louisiana, to comply with USP Chapter <797> sterile compounding standards and all applicable federal law. [7]

A pharmacy located in another state that ships compounded bremelanotide into Louisiana must hold a Louisiana non-resident pharmacy permit and comply with LBP rules. Patients should verify this permit before ordering. The Louisiana Board of Pharmacy's licensee search is publicly accessible and takes under two minutes to use.

Louisiana Medical Practice Act

Under Louisiana Revised Statutes Title 37, §1271, a physician licensed by the Louisiana State Board of Medical Examiners (LSBME) may prescribe any FDA-approved or appropriately compounded drug for any medically appropriate purpose, including off-label use. [8] Prescribing bremelanotide off-label to a male patient, for example, is not prohibited by Louisiana state law, though the prescriber carries the standard duty-of-care obligation to document clinical justification.

No Louisiana-Specific Ban

A review of Louisiana Revised Statutes, the LBP's formulary guidance, and the LSBME's published position statements finds no Louisiana-specific prohibition on bremelanotide prescribing or dispensing. The legal constraints that apply in Louisiana are federal: the FD&C Act, the 503A/503B rules, and DEA scheduling. State law adds procedural layers (prescription format, pharmacist verification, telehealth prescribing standards) but does not independently restrict this drug.

How to Get PT-141 (Bremelanotide) Legally in Louisiana

Step 1. Obtain a Prescription From a Licensed Louisiana Provider

Any physician, nurse practitioner, or physician assistant licensed in Louisiana may prescribe bremelanotide after a proper evaluation. An in-person visit is not legally required. Louisiana adopted the Interstate Medical Licensure Compact and updated its telehealth statute (La. R.S. 40:1223.3) to permit prescribing via synchronous audio-video platforms for patients physically located in Louisiana at the time of the visit. [9] The provider must establish a patient-provider relationship, document history and relevant diagnoses (HSDD in women, off-label in men), review contraindications, and generate a lawful prescription.

Contraindications include cardiovascular disease, uncontrolled hypertension, and concurrent use of naltrexone or other drugs affecting melanocortin receptors. Providers must review blood pressure prior to initiating therapy. [1]

Step 2. Choose an FDA-Approved Product or a Compliant Compounding Pharmacy

FDA-approved Vyleesi: Vyleesi is available at Louisiana retail pharmacies and through mail-order pharmacies. Insurance coverage for HSDD medications remains limited. A GoodRx coupon typically brings the cash price of one auto-injector to roughly $100 to $130, though this varies by pharmacy and coupon availability.

Compounded bremelanotide: If a prescriber documents clinical necessity (e.g., excipient sensitivity), a 503A compounding pharmacy may prepare bremelanotide. The pharmacy must be licensed by the LBP (or hold an LBP non-resident permit), comply with USP <797>, and use pharmaceutical-grade bulk drug substance. Patients should request a certificate of analysis (COA) confirming identity, potency, and sterility for every compounded batch. [10]

Step 3. Avoid Unregulated Online Sources

Numerous websites sell "PT-141" labeled "for research use only." These products are not legal for human use. They are not manufactured under cGMP conditions, carry no sterility guarantee, and their actual peptide content is unverified. Purchasing these products for self-administration violates the FD&C Act's prohibition on obtaining prescription drugs without a valid prescription. [11] A 2020 analysis published in JAMA Network Open found that a significant proportion of peptide products sold through unregulated online vendors failed purity and identity testing. [12]

Clinical Profile of Bremelanotide: What Louisiana Patients Should Know

Mechanism and Efficacy

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It binds MC3R and MC4R in the hypothalamus and limbic system, areas involved in sexual motivation. Unlike PDE5 inhibitors, which act peripherally on vascular smooth muscle, bremelanotide acts centrally on desire pathways. [13]

In the two Phase 3 RECONNECT trials (total N=1,247 premenopausal women with generalized acquired HSDD), women randomized to bremelanotide 1.75 mg subcutaneous reported a mean increase of 1.2 points on the Female Sexual Function Index desire domain versus 0.7 for placebo (P<0.001), and a mean decrease of 11.1 points on the Female Sexual Distress Scale versus 8.0 for placebo (P<0.001) at 24 weeks. [4]

Dosing and Administration

The approved dose is 1.75 mg subcutaneous injection into the abdomen or thigh, administered approximately 45 minutes before anticipated sexual activity. The maximum recommended frequency is one dose per 24 hours, and no more than one dose per day should be used. Patients should be counseled that it does not increase libido on a chronic baseline level the way daily flibanserin does. [1]

Safety Signals Louisiana Patients Should Discuss With Their Provider

Blood pressure increases averaging 6 mmHg systolic and 3 mmHg diastolic occur within 12 hours of dosing and resolve within 12 hours. [1] Focal hyperpigmentation of the face, gingiva, and breasts has been reported with more than eight doses per month. [4] Women with darker skin phototypes may be at higher risk. Nausea affects roughly 40% of users; administering the injection lying down and remaining supine for 30 to 60 minutes after injection reduces this risk in many patients.

Off-Label Use in Men

Bremelanotide's approval is limited to premenopausal women with HSDD. Small open-label studies and case series have explored its use in men with erectile dysfunction or low sexual desire, including a Phase 2 study (N=30) published by Diamond et al. Showing improved erectile function scores with intranasal bremelanotide. [14] These data predate the subcutaneous formulation's approval. Off-label prescribing in men is legally permissible under Louisiana medical practice law, but the evidence base is thinner and providers should document clinical reasoning carefully.

Comparing Legal Pathways: A Quick Reference for Louisiana Patients

| Pathway | Legal in Louisiana? | Prescription Required? | Key Condition | |---|---|---|---| | Brand Vyleesi at retail pharmacy | Yes | Yes | FDA-approved indication or off-label with physician documentation | | Compounded bremelanotide, 503A pharmacy | Yes, with conditions | Yes | Prescriber documents clinical necessity; pharmacy holds LBP permit | | Compounded bremelanotide, 503B facility | Uncertain pending FDA Category determination | Yes | FDA has not finalized 503B bulk-drug status | | "Research chemical" online purchase | No | N/A | Violates FD&C Act for human use | | Telehealth prescription, Louisiana-licensed provider | Yes | Yes | Synchronous audio-video visit; provider licensed in Louisiana |

Regulatory Monitoring: What Can Change

The FDA's bulk-drug list for 503B facilities is updated periodically. If bremelanotide moves from Category 2 to Category 1 (approved for 503B compounding), outsourcing facilities will gain clearer authority to produce it at scale. If it is placed on the Category 2 "do not compound" list, 503B production would be restricted, though 503A patient-specific compounding would likely remain available. [6] Louisiana prescribers and patients should confirm the current FDA determination at the time of any prescribing decision by checking the FDA's compounding guidance directly at fda.gov. [15]

The American Society of Health-System Pharmacists (ASHP) noted in its 2023 compounding guidelines that "the determination of clinical necessity for a compounded preparation when a commercially available product exists requires explicit prescriber documentation and individualized patient assessment." [16] That principle applies directly to bremelanotide in Louisiana.

Telehealth Access to PT-141 in Louisiana: What the Process Looks Like

Louisiana's telehealth prescribing statute (La. R.S. 40:1223.3) requires that a valid patient-provider relationship be established before a prescription is issued. [9] For a controlled substance, a DEA-registered prescriber and a separate DEA telemedicine waiver would be required, but bremelanotide is not scheduled, so standard telehealth rules apply.

A compliant telehealth encounter for bremelanotide includes a structured sexual health history using a validated instrument such as the Female Sexual Function Index (FSFI) or the Female Sexual Distress Scale-Revised (FSDS-R), a review of cardiovascular history and current medications, blood pressure documentation (patient-reported home reading is acceptable per most telehealth protocols), informed consent covering the blood pressure and hyperpigmentation risks, and a sent prescription to a pharmacy of the patient's choosing.

Patients who present without a prior HSDD diagnosis should expect the provider to rule out secondary causes: relationship factors, depression, hormonal insufficiency (including low testosterone in women), and medication side effects (notably SSRIs and oral contraceptives). [17] Treating an underlying cause first is standard of care before initiating bremelanotide.